Table 2.
Clinical characteristics, HCV antibody levels and specific anti‐ENA antibodies in HCV‐positive and healthy control patients
| Patient groups | N | Age (mean±SD) | M/F | HCV antibody ratio (mean±SD) | Antibody [N (%)] | ||
|---|---|---|---|---|---|---|---|
| Anti‐SSA | Anti‐RNP | Scl‐70 | |||||
| HCV antibody positive | 100 | 49.4±16 | 1.5 | 11.2±3.8 | 4 (4%) | 3 (3%) | 3 (3%) |
| HCV and anti‐ENA positive | 14 | 55.1±14.8 | 2.5 | 10.3±5.2 | 4 (28.6%) | 3 (21.4%) | 3 (21.4%) |
| Healthy controls | 100 | 35.2±19.2 | 0.47 | Negative | 0 | 2 (2%) | 1 (1%) |
| Anti‐ENA positive healthy controls | 3 | 26.0±11.8 | 0.50 | Negative | 0 | 2 (66%) | 1 (33%) |